Table 3.

Factors at baseline associated with day 45 evaluation for all patients

Variablea	Data [no., no. (%), or median (range)] for indicated patient(s)			Pb
	Responder (n = 3)	Nonresponder (n = 2)	Undetermined (n = 2)
Age (yr)	52.1 (15.6–77.8)	45.3 (9.8–71.9)	31.5 and 63.9	0.53
Patient risk category				0.29
Allogeneic HSCT	10 (33)	13 (52)	0 (0)
AL	15 (50)	7 (28)	1 (50)
Others	5 (17)	5 (20)	1 (50)
EORTC-defined IA				0.060
Proven	2 (7)	2 (8)	0 (0)
Probable	20 (67)	22 (88)	2 (100)
Possible	8 (27)	1 (4)	0 (0)
Leukocyte count of <100/mm3 at diagnosis	15 (50)	12 (48)	0 (0)	1.00
Receiving corticosteroids	11 (37)	18 (72)	2 (100)	0.014
Cumulative dose of prednisone the week before diagnosis (mg/kg of body wt)	0.0 (0.0–11.0)	7.0 (0.0–28.0)	7.0 and 31.0	0.002
Received immunosuppressive therapy for <1 month	8 (27)	12 (48)	0 (0)	0.16
Received antimold therapy for <15 days	15 (50)	19 (76)	0 (0)	0.057
Concomitant pulmonary infection	8 (27)	8 (32)	0 (0)	0.77
Serum GM antigen value	0.4 (0.0–9.3)	1.1 (0.1–11.0)	0.2 and 4.8	0.039
Patient(s) with value of ≥0.5	14 (47)	15 (60)	1 (50)	0.42
BAL fluid GM antigen value	3.4 (0.1–9.8)	0.4 (0.0–7.0)		0.096
Patients with value of ≥0.5	10 (71)	8 (53)		0.45
Anti-Aspergillus antibody value	3.3 (0.1–181.0)	3.2 (1.0–108.0)	0.2 and 8.1	0.79
Patients with value of ≥12	4 (14)	6 (24)	0 (0)	0.49
Positive mycological examination of respiratory samples	13 (57)	14 (67)	1 (100)	0.55
Positive PCR Aspergillus fumigatus	2 (9)	3 (20)	0 (0)	0.36
Positive PCR Aspergillus spp	13 (57)	4 (29)	1 (100)	0.17
First-line treatment with voriconazole	22 (73)	20 (80)	1 (50)	0.75
Halo sign	19 (63)	14 (56)	0 (0)	0.59

^aHSCT, hematopoietic stem cell transplantation; GVHD, graft versus host disease; AL, acute leukemia; CS, corticosteroids; GM, galactomannan.

^bFisher's exact test or Wilcoxon rank-sum test for responders versus nonresponders.